Skip to content

Christopher R Mccurdy

10 papers in the library · 309 citations · publishing 0-2026

Papers

Sort Most recent Most cited

Pharmacokinetic study of delta-8-tetrahydrocannabinol in male rats using a validated bioanalytical method.

Journal of Analytical Toxicology April 30, 2026 Alexandria S. Senetra, Sushobhan Mukhopadhyay, Yi-Hua Chiang et al.

Delta-8-tetrahydrocannabinol (Δ8THC) has been growing in popularity across the United States due to its reported therapeutic benefits, including pain relief, euphoria, relaxation, and mild psychoactive effects, especially in areas where sale of delta-9-tetrahydrocannabinol (Δ9THC) is illegal. Currently, much debate surrounds Δ8THC regarding its regulatory status and whether this compound is...

The Sigma1 receptor antagonist CM304 potentiates the antinociceptive effects of the cannabinoid receptor agonist delta9-tetrahydrocannabinol in rats and mice.

Pharmacological reports : PR April 1, 2026 Elmira Zolali, Mallory Burns, Sebastiano Intagliata et al.

BACKGROUND: Mu opioid receptor (MOR) agonists are the primary medication class used to treat moderate to severe pain; however, the ongoing opioid overdose crisis underscores the need for alternatives to MOR agonists for pain treatment. Delta9-tetrahydrocannabinol (THC), a cannabinoid CB1 receptor (CB1R) agonist, and sigma1 receptor (σ1R) antagonists elicit antinociceptive effects albeit less...

Implications of Indolethylamine N-Methyltransferase (INMT) in Health and Disease: Biological Functions, Disease Associations, Inhibitors, and Analytical Approaches.

Brain Sciences August 28, 2025 Seif Abouheif, Ahmed Awad, Christopher R Mccurdy 1 citation

Indolethylamine N-methyltransferase (INMT) is a Class 1 methyltransferase responsible for N-methylation of various endogenous and exogenous compounds, including tryptamine, serotonin, and dopamine. This review aims to provide a comprehensive overview of the biological and therapeutic relevance of INMT, emphasizing the human isoform (hINMT), highlighting its structural characteristics, disease...

Effects of cannabis smoke and oral Δ9THC on cognition in young adult and aged rats

Psychopharmacology February 7, 2025 Sabrina Zequeira, Emely A. Gazarov, Alara A. Güvenli et al.

With increasing legalization of recreational and medical cannabis, use of this drug is growing rapidly among older adults. As cannabis can impair cognition in young adults, it is critically important to understand how its consumption interacts with the cognitive profile of aged subjects, who are already at increased risk of decline. The current study was designed to determine how cannabis...

Cannabis smoke and oral Δ9THC enhance working memory in aged but not young adult subjects

bioRxiv (Cold Spring Harbor Laboratory) September 29, 2024 Sabrina Zequeira, Emely A. Gazarov, Alara A. Güvenli et al. preprint

With increased legalization of recreational and medical cannabis, use of this drug is growing rapidly among older adults. As cannabis use can impair cognition in young adults, it is critically important to understand how consumption interacts with the cognitive profile of aged individuals, who are already at increased risk of decline. The current study was designed to determine how cannabis...

Antidepressive effects of the κ-opioid receptor agonist salvinorin A in a rat model of anhedonia.

Behavioural Pharmacology October 1, 2012 Mitchell T Harden, Staci E Smith, Jennifer A Niehoff et al. 37 citations

Salvinorin A (SalvA), the hallucinogenic derivative of the plant Salvia divinorum, is a selective κ-opioid receptor agonist that may also have antidepressant properties. Chronic mild stress (CMS) was applied to male and female Long-Evans rats to model anhedonia common in depression. The progressive loss in preference for a sucrose solution over plain water, a measure of anhedonia, and locomotor...

Opioid receptors and legal highs:Salvia divinorumand Kratom

Clinical Toxicology 2008 Kavita M. Babu, Christopher R Mccurdy, Edward W Boyer 221 citations

Salvia divinorum and Mitragyna speciosa ("Kratom"), two unscheduled dietary supplements whose active agents are opioid receptor agonists, have discrete psychoactive effects that have contributed to their increasing popularity. Salvia divinorum contains the highly selective kappa- opioid receptor agonist salvinorin A; this compound produces visual hallucinations and synesthesia. Mitragynine, the...

The hallucinogen derived from Salvia divinorum, salvinorin A, has kappa-opioid agonist discriminative stimulus effects in rats.

Neuropharmacology September 1, 2007 Catherine B Willmore-Fordham, Daniel M Krall, Christopher R Mccurdy et al. 49 citations

Data from clinical and preclinical studies converge implicating the plant-derived hallucinogen salvinorin A as an important pharmacologic tool; this psychoactive compound may expand scientific understandings on mammalian kappa-opioid receptor systems. Human salvinorin A effects, consistent with kappa-opioid receptor agonism, include antinociception, sedation, dysphoria and distorted...

A unique binding epitope for salvinorin A, a non‐nitrogenous kappa opioid receptor agonist

The FEBS Journal May 1, 2006 Brian E. Kane, Marcelo J. Nieto, Christopher R Mccurdy et al.

Salvinorin A is a potent kappa opioid receptor (KOP) agonist with unique structural and pharmacological properties. This non‐nitrogenous ligand lacks nearly all the structural features commonly associated with opioid ligand binding and selectivity. This study explores the structural basis to salvinorin A binding and selectivity using a combination of chimeric and single‐point mutant opioid...

A Pilot, Dose-Finding, Pharmacodynamic and Pharmacokinetic Study of Orally Administered Botanical Kratom.

Journal of Clinical Psychopharmacology Chad J Reissig, Ling Chen, Srikanth C Nallani et al. 1 citation

Kratom ( Mitragyna speciosa ) is a plant indigenous to Southeast Asia. This pilot study evaluated the pharmacodynamic (PD) effects, safety, and pharmacokinetics (PK) of kratom and several of its alkaloids. Recreational polydrug users (8 participants/cohort; 6 active: 2 placebo, N=40) completed the study. Participants had experience with opioids but were otherwise healthy. This study utilized a...